論文発表


□■ 発表論文 ■□


 2017年

Doki N, Kakihana K, Ashizawa M, et al.
Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302)
IJH https://doi.org/10.1007/s12185-017-2396-9

Motohashi K, Fujisawa S, Doki N, et al.
Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia
Leukemia & Lymphoma, 2017 https://doi.org/10.1080/10428194.2017.1387913

Kako S, Kanda Y, Kato J, et al.
The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS. Hematol Oncol 2017;35:341-349

 2016年

Kanda Y, Kobayashi T, Mori T, et al.
A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. Bone Marrow Transplantation 2016 51, 103–109

 2015年

Shimizu H, Saitoh T, Machida S, et al.
Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. Eur J Haematol. 2015;95:455–460.

Tanaka M, Kanamori H, Matsumoto K, et al.
Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy. Bone Marrow Transplant 2015;50:727-733.

Motohashi K, Fujisawa S, Onizuka M, et al.
Effect of the order of TBI and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2015;50:1476-1479.

Yano S, Mori T, Kanda Y, et al.
Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. Bone Marrow Transplant 2015;50:1299-1305.

 2014年

Nakaya A, Mori T, Tanaka M, et al.
Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy. Biol Blood Marrow Transplant 2014;20:1553-1559.

 2013年

Doki N, Miyawaki S, Tanaka M, et al.
Visceral varicella zoster virus infection after allogeneic stem cell transplantation. Transpl Infect Dis. 2013;15:314-318.

Oshima K, Kanda Y, Nanya Y, et al.
Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation.. Ann Hematol. 2013;92:255-260.

Mori T, Tanaka M, Kobayashi T, et al.
Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant 2013;19:486-491.

 2012年

Shimizu H, Saitoh T, Tanaka M, et al.
Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. Leukemia 2012;26:2469–2473.

Takeuchi M, Nakaseko C, Ohwada C, et al.
Allogeneic hematopoietic stem cell transplantation for primary and secondary myelofibrosis: a retrospective, multicenter study of the Kanto Study Group for Cell Therapy (KSGCT). Journal of Hematopoietic Cell Transplant 2012;1:15-23.

Yokota A, Ozawa S, Masanori T, et al.
Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplant 2012;47:95–100.

 2011年

Sakai R, Kanamori H, Nakaseko C, et al.
Air-leak syndrome following allo-SCT in adult patients: report from the Kanto Study Group for Cell Therapy in Japan. Bone Marrow Transplant 2011;46:379–384.

Nakaseko C, Ozawa S, Sakaida E, et al.
Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol. 2011;93:375–382.

 2010年

Nakasone H, Kanda Y, Takasaki H, et al.
Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia 2010;24:1236-1239.

萩原真紀,金森平和,酒井美和,ほか
関東造血幹細胞移植共同研究グループにおける同種造血幹細胞移植後の生着不全に対する再移植の後方視的検討. 臨床血液 2010,51:390-397.
Hagihara M, Kanamori H, Sakai M, et al.
Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation ―A retrospective survey by Kanto Study Group for Cell Therapy. Jpn J Clin Hematol. 2010,51:390-397.

 2009年

Oda K, Nakaseko C, Ozawa S, et al.
Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT. Bone Marrow Transplant 2009;43:159–167.

Nakasone H, Kanda Y, Ueda T, et al.
Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma. Am J Hematol. 2009;84:809-814.

 2008年

Oshima K, Kanda Y, Yamashita T, et al.
Central Nervous System Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2008;14:1100-1107.

坂巻 壽
関東造血幹細胞移植共同研究グループのこれまでと将来. 臨床血液 2008;49:464-468.

 2007年

藤巻克通,中世古知昭,大島久美,ほか
HBs抗体陽性患者における同種造血幹細胞移植後のB型肝炎ウイルスの再活性化. 臨床血液 2007;48:386-390.
Fujimaki K, Nakaseko C, Oshima K, et al.
Hepatitis B virus reactivation in patients with HBs antibodies after allogeneic hematopoietic stem cell transplantation. Jpn J Clin Hematol. 2007;48:386-390.

 2006年

Kanda Y, Hyo R, Yamashita T, et al.
Effect of Blood Cyclosporine Concentration on the Outcome of Hematopoietic Stem Cell Transplantation From an HLA-Matched Sibling Donor. Am J Hematol. 2006;81:838-844.

Fujimaki K, Mori T, Kida A, et al.
Human Herpesvirus 6 Meningoencephalitis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Int J Hematol. 2006;84:432-437.

 2003年

Nakajima H, Oki M, Kishi K, et al.
Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies. Cli Lab Haematol. 2003;25:383–391.

 2002年

高田覚,岡本真一郎,坂巻壽,ほか
50歳以上の症例に対する同種造血幹細胞移植の検討. 臨床血液
2002;43:904-910.
Takada S, Okamoto S, Sakamaki H, et al.
Outcome of allogeneic stem cell transplantation in patients old than 50years of age. Jpn J Clin Hematol. 2002;43:904-910.

 2001年

藤巻克通,藤澤信,青墳信之,ほか
GVL効果の増強を目的とした免疫抑制剤の早期減量、中止のfeasibilityの検討. 臨床血液 2001;42:680-684.
Fujimaki K, Fujisawa S, Aotsuka N, et al.
Feasibility of early tapering and discontinuation of cyclosprine to intensify thegraft-versus-leukemia effect in patients with advanced hematologic neoplasms. Jpn J Clin Hematol. 2001;42:680-684.

 2000年

Ohashi K, Tanabe J, Watanabe R, et al.
The Japanese Multicenter Open Randomized Trial of Ursodeoxycholic Acid Prophylaxis for Hepatic Veno-Occlusive Disease After Stem Cell Transplantation. Am J Hematol. 2000;64:32–38.



 
Copyright © 2010 KSGCT, All Rights Reserved.